VIRION THERAPEUTICS

Virion Therapeutics is a clinical-stage company developing novel T cell-based immunotherapies for cancer and chronic infectious diseases. We utilize genetically encoded checkpoint modifiers (CPM) to enhance and broaden CD8+ T cell responses to a tumor or chronic infection. In preclinical models of different diseases, addition of CPMs resulted in improved clinical outcomes and survival. Human studies using the first CPM in subjects with chronic HBV are now enrolling (Q3 2023).​... At Virion Therapeutics, We Believe a Future Free of Cancer and Chronic Infectious Diseases Is Within Reach​... With potential applications across a range of cancers and chronic infectious diseases, our proprietary technology provides us with a robust pipeline. Our lead product, VRON-0200, is under investigation as a potential functional cure for the treatment of chronic hepatitis B virus (HBV) - a first-in-human Phase 1b clinical study is now enrolling.

Also known as: Virion, Virion Therapeutics, LLC

Primary location: Philadelphia United States